Australia-UK Platform – Areas of Unmet Medical Need

Fund details

This call is for either Phase 2 or Phase 3 focused platforms, where there is a pipeline of technologies which justifies a platform approach. This call will not support funding for studies aiming to run platforms seamlessly from Phase 2 into Phase 3. 

•  Phase 2 platforms should focus on establishing the efficacy of multiple interventions in a defined patient group or circumstance (which may include sub-groups). The study must focus on interventions with convincing human clinical proof of concept which suggests they may be efficacious. By robustly evaluating efficacy, the study should have the potential to inform future Phase 3 (comparative and cost-effectiveness) trials. 
• Phase 3 platforms should aim to efficiently generate high quality evidence around the clinical and cost-effectiveness of multiple interventions in a defined patient group or circumstance. The focus must be on candidate therapies which have demonstrated some clinical efficiency, but which require further testing in a multi-centre, pragmatic trial to compare against current best practice. 

Areas of particular interest include, but are not limited to: 

• Childhood, brain and prostate cancers 
• Stroke and traumatic brain injuries 
• Neurodegenerative diseases
• Cardiometabolic conditions, including obesity 

Applications to this funding opportunity must describe a platform trial seeking to evaluate a number of specified technologies. Each technology must have sufficient clinical, human proof of concept to justify a definitive efficacy study.